News
23andMe to Report First-Quarter Fiscal Year 2025 Financial Results
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today announced that it will release financial results for the first quarter of its fiscal year 2025 (FY2025) after the close of business on Thursday, August 8, 2024. The Company will host a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s results and report on business progress.
The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A replay of the webcast will be available at the same address following the event. Additionally, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management prior to the earnings call. Starting today, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2025-q1. The Q&A platform will remain open for up to 24 business hours prior to the earnings conference call.
About 23andMe
23andMe is a genetics-led consumer health and therapeutics company, empowering a healthier future. For more information, visit investors.23andme.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s business in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated into this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continuing operations, cash reserves, projected costs, database growth, plans and objectives of management, are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “predicts,” “continues,” “will,” “schedule” and “would,” or in each case, the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot assure you that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond 23andMe’s control) or other assumptions that could cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors,” in the Company’s most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments or otherwise.
The story continues
Contacts
Investor Relations Contact: Ian Cooney, ianc@23andme.com
Media Contact: press@23andMe.com